DeCure for Neurodegeneration with brain iron accumulation 2A
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for neurodegeneration with brain iron accumulation 2A — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurodegeneration with brain iron accumulation 2A maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurodegeneration with brain iron accumulation 2a is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2014 rat study found that 12 weeks of a high-iron diet caused brain iron accumulation, mitochondrial dysfunction, impaired synaptic plasticity and cognition, blood-brain-barrier breakdown, and brain apoptosis. Treatment with the iron chelator deferiprone (50 mg/kg) or the antioxidant n-acetyl cysteine (100 mg/kg) for four weeks attenuated these effects, and the combination of both drugs produced more robust results. The authors state that combined therapy completely restored brain function impaired by iron overload in this animal model.
A 2014 case report of a 13-year-old girl with mitochondrial membrane protein-associated neurodegeneration (a form of NBIA) treated with an iron-chelating agent showed that highly increased brain iron content slowly decreased in the substantia nigra but remained stable in the globus pallidus, as measured by MRI. The estimated iron content was higher by R2* relaxometry compared to R2 relaxometry and quantitative susceptibility mapping, a discrepancy not seen in healthy volunteers.
A 2021 review of NBIA disorders states that there are no proven disease-modifying treatments at present. It notes that therapeutic options remain very limited, though approaches under development include gene therapy, gene editing, and substrate replacement therapies. A 2013 paper on the TIRCON project notes that the most frequent NBIA form is pantothenate kinase-associated neurodegeneration (PKAN) and that the absence of adequately powered randomised clinical trials is due to the rarity of the disease, the lack of patient registries, and fragmentation of therapeutic research worldwide, not a lack of therapeutic options.
A 2014 review on postoperative cognitive dysfunction discusses iron accumulation as a possible mechanism but does not provide clinical trial data for any drug in NBIA patients. What is still missing for NBIA 2A specifically are adequately powered randomised controlled trials, patient registries to enable them, and validated biomarkers to stratify patients by disease stage and iron burden.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS ONE · 2014 · 105 citations · open access
Combined Therapy of Iron Chelator and Antioxidant Completely Restores Brain Dysfunction Induced by Iron Toxicity
AbstractBACKGROUND: Excessive iron accumulation leads to iron toxicity in the brain; however the underlying mechanism is unclear. We investigated the effects of iron overload induced by high iron-diet consumption on brain mitochondrial function, brain synaptic plasticity and learning and memory. Iron chelator (deferiprone) and antioxidant (n-acetyl cysteine) effects on iron-overload brains were also studied. METHODOLOGY: Male Wistar rats were fed either normal diet or high iron-diet consumption for 12 weeks, after which rats in each diet group were treated with vehicle or deferiprone (50 mg/kg) or n-acetyl cysteine (100 mg/kg) or both for another 4 weeks. High iron-diet consumption caused brain iron accumulation, brain mitochondrial dysfunction, impaired brain synaptic plasticity and cognition, blood-brain-barrier breakdown, and brain apoptosis. Although both iron chelator and antioxidant attenuated these deleterious effects, combined therapy provided more robust results. CONCLUSION: In conclusion, this is the first study demonstrating that combined iron chelator and anti-oxidant therapy completely restored brain function impaired by iron overload.
Annals of Clinical and Translational Neurology · 2014 · 27 citations · open access
Brain iron quantification by MRI in mitochondrial membrane protein‐associated neurodegeneration under iron‐chelating therapy
AbstractTherapeutic trials for Neurodegeneration with Brain Iron Accumulation have aimed at a reduction of cerebral iron content. A 13-year-old girl with mitochondrial membrane protein-associated neurodegeneration treated with an iron-chelating agent was monitored by R2 relaxometry, R2* relaxometry, and quantitative susceptibility mapping to estimate the brain iron content. The highly increased brain iron content slowly decreased in the substantia nigra but remained stable for globus pallidus. The estimated iron content was higher by R2* compared to R2 and quantitative susceptibility mapping, a finding not previously observed in the brain of healthy volunteers. A hypothesis explaining this discrepancy is offered.
Tremor and Other Hyperkinetic Movements · 2021 · 20 citations · open access
Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation
AbstractBackground: Neurodegeneration with brain iron accumulation (NBIA) disorders comprise a group of rare but devastating inherited neurological diseases with unifying features of progressive cognitive and motor decline, and increased iron deposition in the basal ganglia. Although at present there are no proven disease-modifying treatments, the severe nature of these monogenic disorders lends to consideration of personalized medicine strategies, including targeted gene therapy. In this review we summarize the progress and future direction towards precision therapies for NBIA disorders. Methods: This review considered all relevant publications up to April 2021 using a systematic search strategy of PubMed and clinical trials databases. Results: We review what is currently known about the underlying pathophysiology of NBIA disorders, common NBIA disease pathways, and how this knowledge has influenced current management strategies and clinical trial design. The safety profile, efficacy and clinical outcome of clinical studies are reviewed. Furthermore, the potential for future therapeutic approaches is also discussed. Discussion: Therapeutic options in NBIAs remain very limited, with no proven disease-modifying treatments at present. However, a number of different approaches are currently under development with increasing focus on targeted precision therapies. Recent advances in the field give hope that novel strategies, such as gene therapy, gene editing and substrate replacement therapies are both scientifically and financially feasible for these conditions. Highlights: This article provides an up-to-date review of the current literature about Neurodegeneration with Brain Iron Accumulation (NBIA), with a focus on disease pathophysiology, current and previously trialed therapies, and future treatments in development, including consideration of potential genetic therapy approaches.
Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) - an integrated strategy under FP7 to improve research, treatment, and care in neurodegeneration with brain iron accumulation
AbstractAims: Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically heterogeneous group of rare hereditary neurodegenerative disorders characterized by high levels of brain iron. Many NBIA cases are characterized by early childhood onset and rapid progression to disability and death. The most frequent form of NBIA is pantothenate kinase-associated neurodegeneration (PKAN). Currently, there is no proven therapy to halt or reverse PKAN or any other form of NBIA. This is especially unfortunate as both the iron accumulation in NBIA and the biochemical defect in PKAN are predicted to be amenable to drug-based treatment. Thus, the absence of adequately powered randomized clinical trials is not due to a lack of therapeutic options but to the rarity of the disease, the lack of patient registries, and the fragmentation of therapeutic research worldwide.
The role of iron accumulation in postoperative cognitive dysfunction
AbstractBackground Postoperative cognitive dysfunction (POCD) is a common neurological complication after anesthesia and surgery,especially prevalent in the elderly.Iron accumulation in the brain is an initial cause of neurodegeneration,it gives rise to neuronal degeneration and necrosis by arousing oxidative stress.Objective This review aims to investigate the role of iron accumulation in POCD.Content The distribution of brain iron,iron metabolism protein function,the relationship of excessive iron levels in the brain and neurodegeneration,as well as the progress of iron accumulation in POCD are described in the article.Trend Iron accumulation may be an important mechanism of POCD,the neuroprotection of iron chelator is expected to provide new target for the management of POCD.
Key words:
Iron accumulation; Neurodegeneration; Postoperative cognitive dysfunction
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
